2026 Annual Meeting | C114 - Autoimmune Neurology: Paraneoplastic

Date Monday 04/20/26

Time 03:30 PM - 05:30 PM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Mar Guasp, MD

Topic(s) Autoimmune Neurology

Learning Objectives Participants should be able to recognize the clinical features of paraneoplastic neurological syndromes (PNS) of the CNS and describe their associations with cancer and the presence of neuronal antibodies that target intracellular or cell-surface neuronal antigens. The course will provide an overview of the recent diagnostic criteria for PNS, highlighting advances in the field, as well as discussing persisting limitations and key points to consider in their application. This course will also cover the importance of characterizing the specific location of the target antigens that has implications for diagnosis, treatment, and prognosis. Lastly, it will show how neuropathological studies are increasing our understanding of the physiopathology of these diseases and can guide the design of treatment strategies.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic

Event Timeline
03:30 PM - 04:05 PM CDT	Speaker	Diagnostic and Treatment Utility of Antigen Characterization: Intracellular vs Cell Surface Mar Guasp, MD
04:05 PM - 04:40 PM CDT	Speaker	Screening for Tumors and Treatment of Paraneoplastic Neurological Syndromes Maarten J. Titulaer, MD, PhD
04:40 PM - 05:15 PM CDT	Speaker	Neuropathological Findings and Implications for the Diagnosis of Paraneoplastic Syndromes Romana Hoeftberger
05:15 PM - 05:30 PM CDT	Q&A	Questions and Answers Mar Guasp, MD, Maarten J. Titulaer, MD, PhD, Romana Hoeftberger

Faculty Disclosures
Mar Guasp, MD	Dr. Guasp has nothing to disclose.
Maarten J. Titulaer, MD, PhD	The institution of Dr. Titulaer has received research support from Dutch Epilepsy Foundations (NEF 19-08). The institution of Dr. Titulaer has received research support from CSL Behring. The institution of Dr. Titulaer has received research support from UCB. The institution of Dr. Titulaer has received research support from Netherlands Organisation for Scientific Research (ZonMW, Memorabel initiative and E-RARE UltraAIE) . The institution of Dr. Titulaer has received research support from Horizon Therapeutics / Amgen. The institution of Dr. Titulaer has received research support from Dioraphte (charity). The institution of Dr. Titulaer has received research support from Guidepoint Global LLC. The institution of Dr. Titulaer has received research support from ArgenX. Dr. Titulaer has received intellectual property interests from a discovery or technology relating to health care. Dr. Titulaer has received publishing royalties from a publication relating to health care.
Romana Hoeftberger	Romana Hoeftberger has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology: Neuroimmunology and Neuroinflammation. Romana Hoeftberger has received personal compensation in the range of $500-$4,999 for serving as a speaker with BMS and UCB Biopharma.

��ɫ��

��ɫ��